This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA.
A new generation of AI-native researchers is leading the way in the war on cancer. This next crop of scientists is AI-native, interdisciplinary—and comfortable challenging assumptions.
The roots of medicine are in the promotion of human welfare, aka humanitarianism. Healthcare AI can either degrade or reinforce this heritage. Who picks the path?
New ACC/AHA recommendations encourage clinicians to take a proactive approach when managing patients with elevated or high blood pressure. The inclusion of renal denervation in this document represents clear progress for a relatively new technology.
The authors of a new commentary in the American Journal of Cardiology argued that well-balanced plant-based diets are good for the heart and good for society as a whole.
Hospitals are still facing tough financial conditions heading into the end of 2022, with the latest National Hospital Flash Report revealing negative margins in October.
This year’s flu season is underway in the United States, and the number of cases is rising, according to the latest flu data from the Centers for Disease Control and Prevention (CDC).
Forbes has announced its annual 30 Under 30 list, highlighting leaders across industries. Within the healthcare space, the list features leaders working to expand access to care and to treat and cure disease.
Carpal tunnel syndrome can be successfully treated without surgery, according to new findings being presented at RSNA 2022 in Chicago. The procedure typically takes just 10 to 15 minutes.
Under terms of the deal, Boston Scientific will pay $10 per share to acquire Apollo Endosurgery, well above the company’s previous day’s close of $6 per share.